Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia 4Lymphoma, T-Cell, Cutaneous 3Lymphoma 3Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Mycosis Fungoides 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Hairy Cell 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Skin Neoplasms 1Recurrence 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1Hematologic Diseases 1Dendritic Cell Sarcoma, Interdigitating 1Bronchiolitis Obliterans Syndrome 1

Interventions

mogamulizumab 4Lenalidomide 3Cyclophosphamide 3Alemtuzumab 2peginterferon alfa-2b 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1cobomarsen 1belinostat 1Zidovudine 1Vincristine 1Raltegravir Potassium 1Prednisone 1Oxaliplatin 1Introns 1Interleukin-15 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Etoposide 1Doxorubicin 1Dexamethasone 1Daclizumab 1Cytarabine 1Cisplatin 1Calcium Dobesilate 1Bortezomib 1B3(Fv)-PE38KDEL recombinant immunotoxin 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia-Lymphoma, Adult T-Cell × B3(Fv)-PE38KDEL recombinant immunotoxin × Clear all
NCT00924170 2023-11-14

Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
18 enrolled 30 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡